Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Johnson and Johnson
Johnson and Johnson
Activities:
Research & Development
Medical Devices
Pharmaceutical
X
LinkedIn
Trending Articles
Neopac showcases latest tube, dispensing and cap innovations at Pharmapack Paris
Highlights include company’s reduced material LowPro caps and world’s smallest child resistant tube
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Indian government bans three medicines owing to health risks
Decision follows strong stand on suspending marketing of all drugs prohibited for sale in other countries, including the US, UK, EU and Australia
You need to be a subscriber to read this article.
Click here
to find out more.
Parenteral preparations: formulation challenges
Parenteral preparations are defined as solutions, suspensions, emulsions for injection or infusion, powders for injection or infusion, gels for injection and implants. They are...
Lonza’s capsule delivers acid-sensitive ingredients to the intestine
The capsule can simplify the manufacturing process to accelerate drug development and expedite first-in-human timelines
Upcoming event
BioProcess International Europe
9-12 April 2024 | Exhibition | RAI Amsterdam
See all
Related Content
Regulatory
FDA grants approval for Johnson & Johnson's antibody for treatment of myeloma
Johnson & Johnson have received accelerated approval of TALVEY, a first-in-class bispecific antibody. TALVEY is a bispecific T-cell engaging antibody that binds to the CD3 receptor
Manufacturing
First-line treatment for patients with metastatic castration-resistant prostate cancer
A company has submitted an NDA for niraparib in combination with abiraterone acetate, in the form of a dual-action tablet (DAT)
Research & Development
F-star Therapeutics announces license agreement with Janssen
The agreement grants Janssen an exclusive license to research, develop, and commercialise bispecific antibodies directed to its therapeutic targets using F-star’s proprietary Fcab and mAb2 platforms
Research & Development
BioMed X and Janssen R&D announce two research groups
The groups will explore research related to autoimmunity and drug delivery
Ingredients
Therapeutic: nipocalimab for myasthenia gravis
The chronic autoimmune disease, myasthenia gravis, affects the skeletal muscles responsible for eye movements, breathing and motion
Research & Development
BioMed X begins research project for oral therapeutics delivery
The collaboration with Janssen Research and Development was facilitated by Johnson & Johnson Innovation
Manufacturing
GEA continuous plant lands ISPE FOYA for Janssen
GEA helps Janssen Belgium to redefine the future pharmaceutical supply chain with ConsiGma 4.0 continuous manufacturing solutions
Subscribe now